Clinical Study
COVID-19 Plasma study to limit complications from coronavirus
This research is being done to develop a possible new therapy for prevention and treatment of coronavirus disease (COVID-19).We would like to study whether human plasma containing antibodies to the SARS- CoV-2 virus could be an option for prevention and treatment of COVID-19. This type of treatment, known as passive antibody therapy, could be a way of rapidly treating patients when there are sufficient numbers of people who have recovered from infection and can donate antibody-containing plasma. We hope that it will either prevent illness caused by coronavirus or lessen the severity of symptoms.
For more information contact:
Evan Heller
evan.heller@hsc.utah.edu
801-587-7573
IRB#: IRB_00136298
| PI: J. Robinson Singleton
| Department: NEUROLOGY
| Approval Date: 2020-10-09 17:53:00
Study Categories: COVID-19 Studies
| Specialties: Infectious Diseases
Who can participate?
Gender: All
Age: Over 18 years old
Volunteers: Healthy Volunteers
Location: In Person
COVID-19 Study
Inclusion Criteria:
- Must be 18 years old or older
- If you wish to participate, you will need to enroll within 96 hours of a high-risk exposure, as defined by the CDC
Exclusion Criteria:
- You cannot participate if you have received blood products, such as a transfusion, etc., in the past 120 days
- You cannot participate if you have a medical, psychiatric, or cognitive illness, or recreational drug/alcohol use that the study doctor feels could affect your safety or ability to participate
- You cannot participate if you have active symptoms of COVID-19 when you are screened for this study. Symptoms include respiratory infection involving cough, fever, shortness of breath.
- You cannot participate if you have laboratory evidence of COVID-19 infection at time of screening
- You cannot participate if you have had certain allergic reactions to blood products
Will I be paid for my time?
Yes